Navigation Links
NIAID and Chinese officials sign agreement to foster TB research in China's Henan province
Date:4/28/2009

Officials from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and from China's Henan Provincial Bureau of Health will meet in Zhengzhou, China, on April 29 to sign an implementation arrangement intended to foster research on tuberculosis, including clinical research on new treatments for multidrug-resistant tuberculosis (MDR TB). The Henan Provincial Bureau of Health and the NIAID plan to develop jointly a collaborative TB research program at the Henan Provincial Chest Hospital.

"The emergence of drug-resistant strains of tuberculosis in China and elsewhere around the world is deeply concerning to public health officials everywhere," says NIAID Director Anthony S. Fauci, M.D. "The implementation arrangement is an important step toward what we expect will be a fruitful collaboration between U.S. and Chinese investigators. It also confirms our shared commitment to finding new ways to lessen the burden of tuberculosis."

NIAID Principal Deputy Director Hugh Auchincloss, M.D., will attend the signing ceremony. "The new initiative linking Chinese and U.S. investigators in the battle against TB is most welcome, especially in light of the recent call by the World Health Organization for expanded international research to combat this devastating disease," Dr. Auchincloss says.

According to the latest available figures from WHO, about 1.3 million people in China developed active TB disease in 2007. Researchers at the new center will carry out several projects, including clinical trials of new drugs or drug combinations designed to treat MDR TB and extensively drug-resistant TB (XDR TB). The WHO estimates that about 5 percent of newly diagnosed TB cases in China are multidrug-resistant, while 26 percent of previously but incompletely treated TB cases are multidrug-resistant. Drug-sensitive strains of TB usually can be treated successfully with a combination of antibiotics, but the lack of potent and affordable second-line TB drugs makes treating MDR and XDR TB extremely difficult. In addition to research leading to new MDR and XDR TB treatment approaches, the investigators also expect to work together to develop improved methods for rapid and accurate diagnosis of drug-sensitive and drug-resistant TB.


'/>"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIAID funds $51M contract to create comprehensive model of immune responses
2. NIAID strengthens and expands Vaccine and Treatment Evaluation Units
3. NIAID scientists identify new cellular receptor for HIV
4. NIAID to convene HIV Vaccine Summit
5. NIAID describes research priorities to fight drug-resistant tuberculosis
6. NIAID to advance B-cell approach to HIV vaccines
7. NIAID creates HIV vaccine discovery branch
8. NIAID awards contracts to search for protein markers of disease
9. NIAID media availability: Seizures following parasitic infection associated with brain swelling
10. NIAID honors AIDS activist Martin Delaney
11. High alcohol consumption increases stroke risk among Chinese men
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare professionals gained a ... held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , As ... independent hearing healthcare providers to help them stay ahead in the industry. At the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Mediaplanet is proud to announce the launch ... Today, which will educate readers on how to take care of all aspects of ... is placed on melanoma. Dancing with the Stars professional, Witney Carson, shares her journey ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... CEO 2017 on May 30th and 31st at The Four Seasons Hotel Boston. ... executives in the life sciences, offering exclusive access to key decision makers who ...
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the ... versatile, patient-centric spinal cord stimulation system. The Nuvectraâ„¢ Algovita SCS System has been FDA ... to be the first in Arkansas to introduce the most powerful SCS system and ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community ... healthiest seniors are located in the Midwest. With the average cost of healthcare rising ... are concerned with both the quality and affordability of where they live. An annual ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 CSSi, the ... for the clinical research industry, is proud to announce ... . The new website features both enriched content and ... experience and enhances the company,s already well-established position as ... "After many months of hard work, ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its commitment ... of directors for the Pharmaceutical Research and Manufacturers ... membership. Biopharmaceutical companies will now have to meet ... to be eligible to join PhRMA. ... board is sending a clear message that being ...
(Date:5/9/2017)... PORTLAND, Ore. , May 9, 2017 /PRNewswire/ ... company that provides technology solutions to improve the ... reported financial results for the first quarter ended ... that our products enable our customers to identify ... them to intervene before events like heart attacks ...
Breaking Medicine Technology: